ArticleCancer discovery2023

STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts.

Leonard Buckbinder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.